Bionumerik Pharmaceuticals, Inc.

Qiuli Huang

Frederick H Hausheer

Harry Kochat

Xinghai Chen

Kochat Haridas

Kesavaram Narkunan

Vincent Gerusz

Pavankumar Nv Petluru

Ye Wu

Jianyan Wang

Andrey Malakhov

Pavankumar N V Petluru

The present invention discloses: (i) two novel deuterated Karenitecin&#xae; analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (ii) methods of synthesis of said novel deuterated Karenitecin&#xae; analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (iii) pharmaceutically-acceptable formulations comprising said novel deuterated Karenitecin&#xae; analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents; and (iv) methods of administration of said novel deuterated Karenitecin&#xae; analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof.

Deuterated analogs of (4S)-4-ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4&#x2032;:6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof

Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.

Compounds and methods for reducing undesired toxicity of chemotherapeutic agents

Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.

Platinum analogs with bis-nitrile-containing ligands

This invention relates to novel salts of medicinal disulfides. The compounds include a terminal sulfonate or phosphonate moiety, and have many uses, such as toxicity reducing agents when administered with many antineoplastic agents.

Medicinal disulfide salts

A process for synthesizing substantially enantiomerically pure L-amino acids, particularly L-&#x3b3;-methylene glutamic acid, and esters and salts thereof. The process includes the derivatization of (2S)-pyroglutamic acid, and the decyclization of the resulting derivative to form the desired end product.

Process for synthesizing L-&#x3b3;-methylene glutamic acid and analogs

This invention relates to novel compositions of matter which either terminate in a sulfhydryl moiety or are disulfides. The compounds also include a terminal sulfonate or phosphonate moiety, and have many uses, such as toxicity reducing agents when administered with many antineoplastic agents.

Growing community of inventors

San Antonio, TX, United States of America

Qiuli Huang